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Greater than 95% of all cervical carcinomas have been found to be associated with “high-risk” human papillomavirus
(mainly types 16 and 18) infections, with the viral E6 and E7 oncoproteins essential for neoplastic development and
maintenance. Interferon-a (IFNa) is used in the treatment of HPV infections yet both in vivo and in vitro data suggest that the
virus has developed mechanisms to avoid the effects of interferon. Here we show that the HPV16 E7 oncoprotein is able to
inhibit the induction of IFNa-inducible genes but has no effect of IFNg-inducible genes. Expression of E7 correlates with the
loss of formation of the interferon-stimulated gene factor 3 (ISGF3) transcription complex. Moreover, in the presence of E7,
p48, the DNA-binding component of ISGF3, was unable to translocate to the nucleus upon IFNa stimulation. A direct
protein–protein interaction was identified between E7 and p48 with the site of interaction within E7 defined as the region
between amino acids 17–37, a domain that includes the binding site for the retinoblastoma protein, pRb. These results
suggest that HPV, via E7, targets p48, resulting in the loss of IFNa-mediated signal transduction and may provide a means
by which HPV can avoid the innate immune system. © 1999 Academic Presss
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sINTRODUCTION
Interferons (IFNs) are cytokines that exhibit potent
ntiviral, antiproliferative, and immunomodulatory prop-
rties brought about through induction of interferon-stim-
lated gene (ISG) transcription (for review see Vilcek and
en, 1996). Many viruses have developed mechanisms
o counteract the actions of IFN, although generally DNA
iruses are more resistant than RNA viruses. For exam-
le, vaccinia virus has developed a number of strategies
o counteract IFN including expression of soluble IFN
eceptors (Lipta´kova et al., 1997) and synthesis of two
roteins specifically to inhibit the activities of the IFN-
nduced kinase, PKR (Carroll et al., 1993; Chang et al.,
992). Adenovirus also inhibits interferon by using an
lternate mechanism in that IFN action is globally inhib-
ted by interference with the signal transduction pathway
ctivated by type I IFNs (Gutch and Reich, 1991; Kalva-
olanu et al., 1991; Leonard and Sen, 1997). Indeed,
denoviruses not only escape the actions of IFN but they
llow other viruses to multiply in IFN-treated, adenovirus-
nfected cells (Anderson and Fennie, 1987). The loss of
hese IFN-inhibitory genes results in greatly reduced or
ven loss of viral replication. Therefore, it is clear that the
nhibition of IFN action is an integral part of many viral
ife cycles.
While type I (IFNa/b) and type II (IFNg) IFNs utilize
ifferent cellular receptors they both utilize JAK-STAT
1 To whom correspondence and reprint requests should be
ddressed. Fax: 161 7 32 40 59 46. E-mail: nmcmillan@medicine.
a.uq.edu.au.305ignal transduction pathways to initiate different, yet
verlapping, subsets of genes (Darnell et al., 1994). Im-
ediate responses to type I IFN are mediated by a signal
ransduction pathway that involves the formation of the
nterferon-stimulated gene factor 3 (ISGF3) transcription
actor complex. ISGF3 is a trans-acting, trimeric complex
omposed of STAT1, STAT2, and the p48 DNA-binding
rotein (also called ISGF3g). ISGF3 translocates to the
ucleus where it binds to a cis element called the inter-
eron-stimulated response element (ISRE), resulting in
nitiation of transcription (Stark and Kerr, 1992). On the
ther hand, IFNg signaling results in the formation
f STAT1 homodimers to form a complex called GAF
gamma-activating factor) that translocates to the nu-
leus where it binds to the gamma-activating sequence
GAS) element, thereby initiating transcription.
Human papillomaviruses (HPVs) are small dsDNA vi-
uses that cause skin and anogenital warts, laryngeal
ondylomas, and cervical cancer (zur Hausen and de
illiers, 1994). Greater than 95% of all cervical cancers
ave been found to be HPV positive, with particular
high-risk” HPV types (16, 18, 31, etc.) most commonly
ound. The HPV E6 and E7 oncoproteins have been
hown to be necessary for the development and main-
enance of cervical carcinoma (Kaur and McDougall,
988). While IFNa is licensed for treatment of genital
arts, the efficacy of this treatment in terms of virological
ure appears to be marginal (Frazer and McMillan, 1997).
ndeed, while clinical trials of IFN treatment for HPV
enital infections have been pursued for 15 years no
tudy has shown even a 50% improvement over the
pontaneous recurrence rate, no matter what the dose or0042-6822/99 $30.00
Copyright © 1999 by Academic Press
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306 BARNARD AND MCMILLANode of delivery (Frazer and McMillan, 1997). For exam-
le, a recent study indicated that IFNa therapy in com-
ination with ablation gives only an 8% increase in com-
lete response over ablation therapy alone (Armstrong et
l., 1996). These results raise the possibility that HPV has
eveloped a mechanism to avoid the effects of IFN.
here is in vitro evidence to support such a hypothesis.
or example, responses to IFNa are dramatically re-
uced in HPV-transformed primary keratinocytes and cell
ines while response to IFNg appears to be unaffected
Woodworth et al., 1992). Furthermore, cells from lesions
nfected with HPV type 16 or 18 seem to show less
esponse to IFNa than those infected with HPV type 6 or
1, known as “low-risk” HPV types (Schneider et al.,
987). Moreover, patients who respond to IFNa treatment
ave been shown to have lower levels of E7 gene ex-
ression than nonresponders (Arany et al., 1995). To-
ether these data suggest that HPV is indeed utilizing a
echanism to bring about the repression of the actions
f IFNa and this mechanism could well be specific for
igh-risk HPV types and the E7 oncoprotein.
The adenovirus E1A protein shares a number of func-
ional homologies with the E7 protein. For example, both
1A and E7 bind to the retinoblastoma gene product,
RB, and related pocket proteins. Interestingly, E1A has
lso been shown to inhibit the effects of IFNa by inhib-
ting the formation of the ISGF3 transcription factor com-
lex (Gutch and Reich, 1991; Kalvakolanu et al., 1991).
ore recently, it was shown that overexpression of p48
n E1A-expressing cells resulted in the reestablishment
f IFNa signaling, implicating p48’s role in the E1A-
ediated block to signaling (Leonard and Sen, 1997).
Based on the sequence and functional similarities
etween E1A and E7, plus the clinical and in vitro data,
e decided to address the question of HPV16 E7 involve-
ent in the repression of the effects of IFNa. Here we
how that the expression of E7 in an HPV-negative hu-
an epithelial cell line results in significantly reduced
FIG. 1. Induction of PKR mRNA in HaCaT cells. (A) HaCaT cells expre
ith 500 IU/ml IFNa2b for the times indicated before total RNA was extr
nalysis. Fold induction was corrected against the levels of the houseke
n HaCaT cells 6 HPV16 E7. HaCaT cells transfected with pSV2neo an
efore total RNA was extracted and PKR mRNA levels were determined
gainst the levels of the housekeeping gene, HPRT, and this result repnduction of ISG synthesis. This inhibition could be cor-
elated with the loss of the transcription complex ISGF3
n E7-expressing cells, but not in control cells. The in-
bility of p48 to move to the nucleus upon IFNa stimu-
ation was correlated with the expression of E7. Further-
ore, we identified a protein–protein interaction be-
ween HPV16 E7 and the DNA-binding component of
SGF3, p48. Together, these data suggest that HPV tar-
ets p48, via the E7 protein, resulting in the loss of ISGF3
ormation and thereby reducing the transcriptional acti-
ation of ISGs. This finding provides a possible means by
hich HPV could avoid IFN and may in part explain the
aried results obtained with IFN in the treatment of gen-
tal warts.
RESULTS
7 abrogates the induction of PKR mRNA by IFNa
To determine the effect of E7 expression on the induc-
ion of interferon-stimulated genes, we transfected the
7 gene under the control of the CMV promoter into the
PV-negative human epithelial cell line, HaCaT. E7 ex-
ression was confirmed by Northern blot analysis (data
ot shown). Both HaCaT and HaCaT-E7 cells were
reated with 500 IU/ml of IFNa and assayed for induction
f the PKR, a well-defined ISG, by Northern blot and
hosphorImager analysis. The housekeeping gene
PRT was used as an internal control to normalize data
n all experiments. A time course for PKR mRNA induc-
ion indicated that in the absence of E7 expression,
aximal PKR mRNA induction occurred at 12 h posttreat-
ent, reaching approximately 12-fold induction (Fig. 1A).
his indicated the HaCaT cells were able to induce a
ene in response to IFNa. However, in HaCaT cells
xpressing E7, no induction of PKR was observed (Fig.
A). Next, we decided to investigate PKR induction at a
ingle time point (16 h post-IFNa treatment) using mul-
iple, independent transfections. A consistent lack of PKR
PV16 E7 (black bars) or vector-only controls (white bars) were treated
nd PKR levels were determined by Northern blot and PhosphorImager
ene, HPRT. (B) PKR mRNA induction levels at 16 h post-IFNa treatment
r pCMV16E7 or pCMV only were treated with 500 IU/ml IFNa for 16 h
thern blot and PhosphorImager analysis. Fold induction was corrected
s data from three experiments.ssing H
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307HPV E7 BLOCKS IFN SIGNALINGRNA induction was observed in cells expressing E7
ompared to a 5-fold induction in control cells (Fig. 1B).
aken together, these results indicate that the presence
f E7 expression in HaCaT cells results in the abrogation
f PKR mRNA induction following IFNa treatment. Anal-
sis of the 59 UTR of both the mouse and the human PKR
enes indicates that an ISRE site is present and abso-
utely required for induction by type 1 IFNs (Kuhen and
amuel, 1997).
FNg signaling is not affected by E7
Given that IFNa signaling to PKR appeared to be
brogated in E7-expressing HaCaT cells we wondered
hether the signaling pathway mediated by IFNg was
imilarly affected. We therefore performed Northern blot
tudies on stable E7-expressing and control HaCaT cell
ines to determine the effect of E7 expression on the
nduction of IRF-1 and GBP. Both these genes are re-
ponsive to IFNg stimulation via the GAS element al-
hough GBP appears to also require the ISRE element in
ts promoter for full activation (Lew et al., 1991). PKR is
ot responsive to IFNg. Cells were treated with IFNa
500 IU/ml) or IFNg (100 IU/ml) for 16 h and the levels of
RNA induction of IRF-1 and GBP were measured. As
efore, PhosphorImager analysis of HPRT was used to
ormalize results. As expected, IFNg treatment resulted
n the induction of both IRF-1 and GBP mRNA in control
ells by 7.5- and 39-fold, respectively (Fig. 2). Interest-
ngly, IFNg-mediated gene induction was not down-reg-
lated in E7-expressing HaCaT cells but was in fact seen
o be enhanced with IRF-1 induced 15.5-fold while GBP
as induced 51-fold. Therefore, we concluded that the
resence of E7 did not diminish IFNg-mediated signal-
ng.
SGF3 formation is disrupted by E7
Our results indicated that E7 was able to block IFNa-
ediated signaling events but not those of IFNg. The
FIG. 2. Induction of IFNg-responsive genes. HaCaT cells transfected
ith pSV2neo and either pCMV16E7 or pCMV only were treated with
00 IU/ml IFNa or 100 IU/ml IFNg for 16 h before total RNA was
xtracted and mRNA levels were determined by Northern blot and
hosphorimager analysis. Fold induction was corrected against the
evels of the housekeeping gene, HPRT.ignal transduction pathways by which these cytokines
ediate gene expression is now well established. IFNa
equires the formation of the transcription factor ISGF3, a
rimeric protein complex consisting of STAT1, STAT2, and
48 (ISGF3g), while IFNg signaling results in the forma-
ion of a transcription factor consisting of a STAT1 ho-
odimer. In order to delineate a mechanism by which E7
s able to block IFNa signal transduction we decided to
etermine whether E7-expressing HaCaT cells were
ble to form functional ISGF3. Cells were treated for 2 h
ith 500 IU/ml of IFNa before nuclear extracts were
repared and bandshift assays performed using the
SRE from ISG15. Background levels of ISGF3 were ob-
erved in control cells (Fig. 3, lane 1) while treatment
ith IFNa resulted in ISGF3 formation (lane 2). However,
n HaCaT cells expressing E7, ISGF3 formation was lost
o near background levels and a faster migrating product
bserved (lanes 3, 4, and 5). The specificity of the probe
as demonstrated by the ability of cold ISRE to compete
way ISGF3 (lane 6). This result indicates that the ex-
ression of E7 results in the loss of ISGF3 formation and
s consistent with the loss of IFNa-mediated gene induc-
ion in E7-expressing cells.
FNa-induced p48 translocation to the nucleus is
nhibited in E7-expressing HaCaT cells
In the process of signal transduction, IFNa induces
he rapid formation of ISGF3, which is subsequently
ranslocated to the nucleus. It is unclear whether the
NA-binding p48 component of ISGF3 independently
ranslocates to the nucleus before association into the
rimeric ISGF3 complex or whether its translocation is
art of the complex. It has been suggested that both
ariations on this event occur. Evidence in the literature
as suggested that, analogous to E1A, the p48 compo-
ent of ISGF3 may be the target through which E7 acts to
nhibit ISGF3 formation. To ascertain whether E7 affected
he passage of p48 to the nucleus, immunofluorescence
or p48 was carried out on HaCaT, HaCaT-neo, and
aCaT-E7 cells treated with IFN-a. HaCaT-neo cells
howed a slightly slower translocation of p48 to the
ucleus when compared to the parental cell line, HaCaT.
FIG. 3. Gel-shift assay for the formation of ISGF3. HaCaT cells were
reated 6 500 IU/ml IFNa for 2 h before whole-cell lysates were
repared and mixed with a radiolabeled ISRE element from the ISG15
ene. Lane 1, HaCaT-neo control; lane 2, HaCaT-neo 1 IFNa; lane 3–5,
hree independent transfections of HaCaT-E7 treated with IFNa; lane 6;
aCaT-neo 1 IFNa 1 cold ISRE; and lane 7, HaCaT neo control.
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308 BARNARD AND MCMILLANuclear translocation of p48 occurred in HaCaT-neo
ells at 2 h post-IFN-a treatment (Fig. 4B) while in pa-
ental HaCaT cells translocation to the nucleus occurred
t 1.5 h (data not shown). In HaCaT-E7 cells p48 nuclear
ranslocation was lost, with all p48 remaining in the
ytoplasm at all times tested (Figs. 4E and 4F). This was
imilar to cells that had received no IFN-a treatment
Figs. 4A and 4D). Interestingly, by 2.5 h p48 was ob-
FIG. 4. Immunofluorescence analysis of IFNa-induced p48 transloca
ith 500 IU/ml IFNa from 0 to 3 h and then three-step immunofluores
ntreated. (B) HaCaT-neo 1 2 h IFNa treatment. (C) HaCaT-neo 1 2.5 h
F) HaCaT-E7 1 2.5 h IFNa treatment. (G) HaCaT cells double-stained
ytoplasm and nucleus, respectively.erved to have largely moved out of the nucleus in
aCaT-neo cells (Fig. 4C), while p48 remained cytoplas-
ic in HaCaT-E7 cells after 2.5 h of IFNa treatment (Fig.
F). It can be concluded that the majority of p48 resides
n the cytoplasm and is rapidly translocated to the nu-
leus upon treatment with IFNa. However, in cells ex-
ressing E7, p48 was not observed to translocate to the
ucleus.
the nucleus. HaCaT-neo control cells or HaCaT-E7 cells were treated
for p48 was performed (see Materials and Methods). (A) HaCaT-neo
eatment. (D) HaCaT-E7 untreated. (E) HaCaT-E7 1 2 h IFNa treatment.
nti-cytokeratin (green) and propidium iodide (red) to indicate the celltion to
cence
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309HPV E7 BLOCKS IFN SIGNALING7 and p48 interact
As E7 is able to inhibit both the formation of ISGF3 and
he nuclear translocation of p48 we considered possible
echanisms by which such an inhibition might be
chieved. STAT1 was clearly not involved as IFNg sig-
aling was not affected by E7 expression. Previous re-
orts have shown that E1A, an adenovirus protein that is
functional homolog to E7, was able to abrogate ISGF3
ormation and that this formation could be restored by
he addition of IFNg-treated cell extracts. Interestingly,
48 is an IFNg-responsive gene. Evidence that this was
he factor affected in E1A-expressing cells was provided
y the observation that the expression of p48 restored
SGF3 formation and IFN responses to these cells. These
ata indicate that E1A was affecting the activity and/or
evel of p48. The p48 protein is essential to immediate
FNa/b signaling as evidenced by the mutant cell line,
2A, which has no p48, resulting in complete loss of
FNa-mediated gene induction (John et al., 1991). To
scertain if the actual levels of p48 were being affected
n our E7-expressing cells, Western blot analysis was
ndertaken. Comparison of p48 levels in HaCaT cells,
aCaT-neo control cells, and HaCaT-E7 cells revealed
o significant differences, indicating that the presence of
7 was not affecting overall p48 levels (Fig. 5A). As
xpected, p48 was detected in 2fTGH cells (positive
ontrol) but not in U2A cells (negative control). Further-
ore, STAT1 and STAT2 levels were also unaffected by
7 (Fig. 5A), indicating that gross changes in ISGF3
omponent proteins were not occurring.
Therefore we investigated the possibility that E7 and
48 were interacting directly. Interestingly, previous stud-
es have shown that full-length GST-E7 is able to interact
ith an unknown protein of 45–49 kDa (Antinore et al.,
996). GST-E7 was mixed with HaCaT cell extracts (as a
ource of p48) and p48 complexes were immunoprecipi-
ated using an anti-p48 antibody and protein G–Sepha-
ose. Complexes were washed and subjected to SDS–
FIG. 5. p48 levels in E7-expressing cells and interaction of GST-E7
7-expressing or control stable cell lines, as well as 2fTGH fibroblast
12% SDS–PAGE gel, Western blotted, and analyzed for p48, STAT1, o
ane 4, 2fTGH positive control; lane 5, U2A negative control. (B) Cell extra
y immunoprecipitation (I.P.) with rabbit anti-p48 polyclonal antibod
oimmunoprecipitation of GST-E7 by Western blotting with mouse anti-
, I.P. with nonspecific Ab control; lane 4, I.P. minus GST-E7; lane 5, I.P.
, I.P. with GST; lane 9, 200 ng GST.AGE before the presence of GST-E7 in these complexes
as detected by Western blot using an E7-specific
onoclonal antibody. GST-E7 was detected only in com-
lexes precipitated by the anti-p48 antibody (Fig. 5B, lane
) and was not found in reactions were the anti-p48
ntibody was not present (lane 2) or a control antibody
sed (lane 3). The E7 detected was not derived from the
ell extract as evidenced by reactions without GST-E7
dded (lane 4). Furthermore, GST alone did not react with
48 or the anti-E7 antibody (lane 8). These results indi-
ate that HPV16 E7 interacts directly with p48 and pro-
ides a possible mechanism to explain the loss of IFNa
ene induction in E7-expressing cells.
he N-terminus of E7 is the interacting domain
Previous studies have shown that full-length GST-E7
nteracts with an unknown band at 45–49 kDa (Antinore
t al., 1996) and this interaction could be narrowed down
o amino acids 2–32 (Dyson et al., 1992). As our data
how that E7 interacts with p48, we wished to determine
hich region of the E7 protein was responsible. E7 is a
8-amino-acid protein and a number of regions have
reviously been functionally defined. The pRB, p107, and
yclin-binding domain lies between amino acids 16 and
7, as do the casein kinase II phosphorylation sites,
hile two zinc-finger-binding domains that interact with
embers of the AP1 family of transcription factors lie at
he C-terminal end of the E7 protein. We therefore de-
ided to investigate which region of E7 was able to bind
o p48 by using E7 peptides as bait to precipitate p48.
ased on the report of Dyson et al. (1992) indicating that
he region of interaction lay within the first 32 amino
cids of E7, we chose two peptides from HPV16 E7, 1–20
nd 17–37. The peptides were conjugated to Sepharose
eads and equal amounts of peptide were incubated
ith in vitro translated p48 protein before being washed
nd p48 detected. In vitro translated p48 gave a 48-kDa
and that reacted with the anti-p48 antibody (Fig. 6, lane
48. (A) Cell extracts were prepared from HaCaT and HaCaT-derived
A mutant fibroblast cell lines, and 10 mg total cell protein was run on
levels. Lane 1, HaCaT; lane 2, HaCaT-neo control; lane 3, HaCaT-E7;
re prepared from HaCaT cells and 1 mg of GST-E7 was added, followed
and protein G–Sepharose. Immunoprecipitates were analyzed for
onoclonal Ab. Lane 1, cell extract; lane 2, I.P. minus anti-p48 Ab; lane
ST-E7 and anti-p48 Ab); lane 6, blank lane; lane 7, 200 ng GST-E7; lanewith p
and U2
r STAT2
cts we
y (Ab)
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310 BARNARD AND MCMILLAN) while two nonspecific bands were observed in both
48 and blank lysate (lanes 9 and 10). Peptide GF103
amino acids 17–37) specifically interacted with p48 (lane
) while peptide GF101 (amino acids 1–20) and Sepha-
ose beads alone were unable to interact (lanes 2 and 3).
he interaction was specific to peptide GF103 as the
nteraction was ablated by the addition of free peptide
F103 (lane 5). Therefore, the region within E7 respon-
ible for mediating interaction with p48 lies between
mino acids 17 and 37.
DISCUSSION
It is probable that all viruses successful in their en-
eavors of host invasion and replication must in some
ay avoid the effects of IFN. This may be as simple as
eplicating and exiting before IFN has the opportunity to
nforce antiviral effects or may involve specific mecha-
isms to evade or inactivate the IFN system. This study
escribes the ability of the HPV16 E7 oncoprotein to
isrupt the IFNa signal transduction pathway. Our data
how that genes responsive to IFNa are not induced in
7-expressing cells. The mechanism of this impairment
ppears to be due to the impairment of the formation of
SGF3 via the ability of E7 to directly bind to p48. One
ossible explanation for the loss of signaling is that the
irect binding of E7 to p48 prevents its association with
TAT1 and STAT2, thus causing loss of ISGF3 formation
nd therefore signal transduction. Previous studies with
1A have shown that E1A can also block IFNa signaling
Gutch and Reich, 1991; Kalvakolanu et al., 1991) as well
s IFNg signaling in some cases (Leonard and Sen,
996). The signaling pathway was restored by the addi-
ion of IFNg-treated cell extracts (Gutch and Reich, 1991)
r the overexpression of p48 in E1A-expressing cells
Leonard and Sen, 1997). It has been suggested that this
ay occur by E1A expression decreasing levels of p48
nd STAT1 in cells. However, we did not note any differ-
nces in the levels of p48, STAT1, or STAT2 between our
ontrol and E7-expressing cells (Fig. 5A), suggesting that
FIG. 6. Interaction of HPV16 E7 peptides with p48. HPV16 E7 pep-
ides GF101 (amino acids 1–20) and GF103 (amino acids 17–37) were
onjugated onto Sepharose beads and combined with in vitro trans-
ated (i.v.t.) p48. Presence of i.v.t. p48 was analyzed by Western blot
sing rabbit anti-p48 polyclonal Ab. Lane 1, GF103 1 i.v.t. p48; lane 2,
F101 1 i.v.t. p48; lane 3, blank Sepharose 1 i.v.t. p48; lane 4, GF103 1
ree GF103 peptide 1 i.v.t. p48; lane 5, GF101 1 free GF101 peptide 1
.v.t. p48; lane 6, GF103 1 blank rabbit reticulocyte lysate; lane 7,
F101 1 blank rabbit reticulocyte lysate; lane 8, blank Sepharose 1
lank rabbit reticulocyte lysate; lane 9, i.v.t. p48; lane 10, blank rabbit
eticulocyte lysate.he absolute level of these proteins was not the reason
ignaling was lost. Furthermore, IFNg signaling was not
ffected (Fig. 2) by E7, indicating that STAT1 was fully
unctional.
The loss of response to IFNa in HaCaT cells express-
ng HPV16 E7 clearly demonstrated repressed induction
f the IFNa-stimulated gene, PKR. Further studies indi-
ated other ISGs inducible by IFNa to be affected in a
imilar manner to PKR, including 2-5A oligoadenylate
ynthetase (data not shown). Furthermore, it has been
hown that the 6-16 gene expression is repressed by
PV16 E7 in a dose-dependent manner (Perea et al.,
997). These data suggest that the inhibition of the ef-
ects of IFNa are acting via a broad mechanism affecting
ignaling rather than an ISG-specific contrivance. It has
et to be shown that the presence of E7 has functional
elevance in terms of the antiviral properties of IFNa.
owever, the expression of E7 has been correlated with
esistance to the anti-proliferative effects of IFNa (Moro
t al., 1998; and our unpublished data).
IFNg signaling appeared to be enhanced by the pres-
nce of E7 as evidenced by the increased levels of
RNA for both IRF-1 and GBP (Fig. 2). One possible
xplanation is that with E7 binding to p48 the STAT1
omponent active in both IFNa and IFNg signaling path-
ays is now free to be exclusively used in IFNg signaling
nd thus leading to improved IFNg-inducible ISG induc-
ion. A certain degree of cross-talk between IFNa and
FNg signaling pathways has been observed previously
Bluyssen et al., 1995), where some ISGF3 formation was
bserved upon IFNg treatment. In E7-expressing cells
his may not occur and could allow enhanced IFNg
ignaling.
The evidence presented here suggests that the mech-
nism by which HPV16 avoids the effects of IFN is via E7
isrupting ISGF3 formation, presumably via a direct in-
eraction with p48. However, other mechanisms may also
e at work. For example, E6 has been shown to interact
irectly with IRF-3 (Ronco et al., 1998). Nevertheless, our
ata indicate that the ratio of E7 to p48 may play a role
n determining a response to IFNa. A patient with higher
evels of p48 (or lower levels of E7) may be more likely to
espond to IFN treatment. This hypothesis is supported
y the observation that ISGF3 induction is diminished in
number of HPV-positive cell lines (HeLa, SiHa, and
aski) but can be restored if p48 protein is added or the
ells were pretreated with IFNg (Petricoin et al., 1994).
urthermore, patients that do not respond to IFNa treat-
ent for HPV-positive condylomas have higher levels of
7 mRNA than patients that were able to respond (Arany
t al., 1995). These observations lead us to speculate
hat increasing p48 levels in cells may improve IFNa
esponsiveness in patients infected with HPV. This could
e achieved by pretreatment with IFNg or retinoic acid.
Immunofluorescence studies indicated that expres-
ion of E7 resulted in the loss of nuclear translocation of
48. HaCaT-neo cells were observed to have slightly
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311HPV E7 BLOCKS IFN SIGNALINGlower nuclear translocation of p48 to the nucleus when
ompared with the parental cell line, HaCaT. The effect of
7 on nuclear translocation of p48 appears to link E7 to
he p48 component of ISGF3 and hence to the failure to
etect ISGF3 in the nucleus of E7-expressing HaCaT
ells. Whether p48 normally translocates to the nucleus
s part of ISGF3, or independently from STAT1/2 het-
rodimers, the E7-mediated failure of p48 to move to the
ucleus results in the loss of ISGF3 formation in the
ucleus of E7-expressing HaCaT cells.
Finally, the presence of the p48-binding site within
PV16 E7 appears to colocalize to the region also in-
olved in interaction with the retinoblastoma protein
pRb). The functional implications of this finding are not
nown and are currently under investigation. However,
he result is surprising given that the region of E1A
hought to inhibit IFN signaling is homologous to the first
5 amino acids of E7 (Gutch and Reich, 1991).
A number of observations indicative of the loss of IFN
esponses and resultant development of neoplasia dem-
nstrate the importance of IFN in tumor suppression.
eletion of the chromosome 9p22 IFNa gene locus has
een found among tumors, including cervical carcino-
as, and many neoplasias have been found to have
eletions or alterations that affect the IFN system, includ-
ng IFN signaling in melanoma (Linge et al., 1995; Wong
t al., 1997), deletion of IFN genes in glioma (Miyakoshi
t al., 1990), and deletion of IRF-1 in leukemia (Willman et
l., 1993). The role of E7 in blocking IFN responses in
ervical neoplasia remains to be determined but the data
resented here indicate that E7 is able to block IFN-
ediated signaling. This would allow HPV-infected cells
o avoid the innate responses of the immune system and
ay be a possible mechanism of tumor promotion in
PV-induced cancer.
MATERIALS AND METHODS
Plasmids and cell lines. pCMV16E7, containing the
PV16 E7 oncogene, was provided by Karen Malcolm
CICR, Brisbane, Australia). pSVbgal was purchased
rom Promega (Australia). The various DNA constructs
ncompassing interferon-stimulated genes are detailed
s follows. pBS-PKR 84 and pBS-IRF-1 were a generous
ift from Dr. Bryan Williams (Cleveland Clinic Foundation,
leveland, OH). ISGF3-g-38-1, consisting of the p48/
SGF3-g gene cloned into pBluescript SK, was a gener-
us gift from Dr. David Levy (New York University School
f Medicine, New York). HaCaT cells were a gift from Dr.
orbert Fusenig (Deutsches Krebsforschungszentrum,
eidelberg, Germany) and were cultured in DMEM (CSL
iosciences, Melbourne, Australia) supplemented with
0% fetal calf serum (CSL Biosciences), 100 units/ml of
enicillin and streptamycin, and 292 mg/ml L-glutamine.
table E7-expressing cell lines were established by co-
ransfection with either 10 mg of pCMV16E7 and 2 mg
SV2neo or 10 mg of pcDNA3neo16E7 using DOTAPransfection reagent (Boehringer Mannheim, Sydney,
ustralia) according to the manufacturer’s instructions.
fter 48 h, cells were selected with 500 mg/ml G418
Boehringer Mannheim), and resistant colonies were
ooled and maintained under selection.
Northern blot analysis. Cells (stable or 48 h post trans-
ection) were treated with 500 IU/ml interferon-a (a gift
rom Schering-Plough, Sydney, Australia) or 100 IU/ml of
nterferon-g (Life Technologies, Melbourne, Australia) or
eft untreated for times indicated. Cells were then
craped into 2 ml of Trizol Reagent (Life Technologies)
nd total cell RNA was extracted according to the man-
facturer’s instructions. Equal quantities of RNA were
repared and subjected to denaturing electrophoresis
n a 1.5% agarose gel containing formaldehyde. The RNA
as transferred to Hybond-N1 nylon membrane (Amer-
ham, Sydney, Australia) and cross-linked to the mem-
rane using a UV Stratalinker (Stratagene, La Jolla, CA).
he blots were prehybridized in a solution containing 53
SC, 53 Denhardt’s solution, 0.5% SDS, and 20 mg/ml
onhomologous DNA for 1 h at 65°C before the addition
f the 32P-labeled DNA probe followed by incubation
vernight at 65°C. Membranes were washed twice for 10
in at room temperature in wash solution 1 (23 SSC,
.05% SDS), followed by two washes for 10 min each at
5°C in wash solution 2 (0.13 SSC, 0.1% SDS) before
hosphorImager (Molecular Dynamics, Sunnyvale, CA)
nalysis. All expression was normalized against the
PRT housekeeping gene.
Electrophoretic mobility shift analysis. HaCaT-E7 and
aCaT-neo cells were treated with 500 IU/ml inter-
eron-a or 100 IU/ml interferon-g or left untreated for 2 h
t 37°C. Nuclear extracts were prepared from these cells
s follows. Cells were washed twice in ice-cold PBS.
ells were then scraped into PBS, pelleted, and resus-
ended in 5 vol of Buffer A (10 mM HEPES, pH 7.9, 1.5
M MgCl2, 10 mM KCl, 0.5 mM dithiothreitol (DTT), 0.2
M PMSF). Cells were then pelleted and resuspended
n 3 vol of buffer A. Cells were incubated on ice for 10 min
efore 300 strokes with a dounce homogenizer. The
uclei were pelleted by centrifugation at 10,000 g and
esuspended in a 12 vol of Buffer B (20 mM HEPES, pH 7.9,
5% glycerol, 1.5 mM MgCl2, 20 mM KCl, 0.2 mM EDTA,
.5 mM DTT, 0.2 mM PMSF), and an equal volume of
uffer C (20 mM HEPES, pH 7.9, 25% glycerol, 1.5 mM
gCl2, 1.2 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM
MSF) was added dropwise while mixing. The solution
as mixed for 30 min at 4°C and centrifuged at 10,000 g,
nd the supernatant was saved as the nuclear extract.
he ISRE probe was made by annealing synthesized
ense (59TCGACCCTTCTGAGGAAACGAAACCAG39) and
ntisense (59ACTGGTTTCGTTTCCTCAGAAGGGTCG39)
ligonucleotides from the ISRE promoter present within
he ISG15 gene. The ISRE probe was end-labeled using
g-32P]ATP (ICN Biomedicals, Sydney, Australia) and T4
olynucleotide kinase (Boehringer Mannheim). Nuclear
xtract (15 mg) was combined with 2 mg poly(dI:dC)
( 32
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312 BARNARD AND MCMILLANSigma, Sydney, Australia), and 30,000 cpm of [g- P]ATP-
abeled ISRE probe in binding buffer (final concentration
0 mM HEPES, pH 7.9, 10% glycerol, 60 mM NaCl, 5 mM
gCl2, 4 mM Tris–Cl, pH 7.9, 1 mM DTT, 0.6 mM EDTA)
n a final volume of 30 ml. Samples were incubated at
oom temperature for 20 min before being subjected to
lectrophoresis on 5% polyacrylamide gels using 0.53
BE (0.045 M Tris–borate, 0.01 M EDTA).
Immunofluorescence. HaCaT-neo and HaCaT-E7 cells
ere seeded in eight-chamber culture slides and cul-
ured as described previously. Cells were treated with
00 IU/ml IFNa for time periods from 0 to 3 h, following
hich cells were washed in 13 PBS and fixed in ace-
one. Cells were then permeabilized in 0.5% Triton X-100
n PBS, rinsed in PBS, and then blocked in 0.5% bovine
erum albumin (BSA) in PBS. All antibodies were diluted
n 0.1% BSA in PBS. Primary incubation was with rabbit
nti-p48 IgG (Santa Cruz Biotechnology, Santa Cruz, CA)
iluted to 1:50, followed by the secondary incubation
ith swine anti-rabbit IgG–biotin diluted to 1:100 and
ertiary incubation with streptavidin-FITC diluted to 1:100.
nti-cytokeratin (AE1/AE3, ICN Biomedicals, Australia)
as used at 1:200 and propidium iodide at 2 mg/ml to
tain the cytoplasm and nucleus, respectively.
Coimmunoprecipitation and Western blot analysis. Ha-
aT cells were lysed into cell lysis buffer (250 mM NaCl,
0 mM HEPES, pH 7.5, 0.1% Nonidet-P40, 10 mM sodium
luoride, 5 mM EDTA, 5 mM DTT, 1 mM PMSF), the NaCl
oncentration was adjusted to 750 mM, and lysates were
recleared against protein G–Sepharose (Sigma) for 1 h
t 4°C. Lysates were dispensed into 500-ml aliquots
approximately 1–4 3 106 cells/aliquot). GST-E7 fusion
rotein (1 mg) (a gift from Dr. Germain Fernando, CICR,
risbane, Australia) was added to the cell lysate and
ixed on a rotary mixer at 4°C for 30 min. Rabbit anti-
48/ISGF3-g polyclonal antibody (Upstate Biotechnology,
ake Placid, NY) was mixed with the lysate at a dilution
f 1:1000 at 4°C for a further 30 min. Protein–antibody
omplexes were mixed with protein G–Sepharose at 4°C
or 30 min, before the complex was washed 5 times in
BS 1 1% Tween 20, resuspended in SDS–PAGE loading
uffer (stock 23; 100 mM Tris–HCl, 4% SDS, 0.2% bro-
ophenol blue, 20% glycerol), and boiled for 5 min. The
recipitant was subjected to SDS–PAGE using a 12% gel
nd transferred onto Hybond-C nitrocellulose membrane
Amersham) before the membrane was blocked in 5%
kim milk powder in PBST (13 PBS, 0.05% Tween 20).
he membrane was probed with mouse anti-E7 mono-
lonal antibody (6D) diluted 1:10,000 in 2.5% skim milk,
ollowed by an HRP-conjugated rabbit anti-mouse anti-
ody (Silenus-Amrad, Melbourne, Australia), and visual-
zation was achieved using enhanced chemiluminence
ECL) according to the manufacturer’s instructions (Am-
rsham).
Western blot. Cell lysates were prepared from 2fTGH,
2A, HaCaT, HaCaT-neo, and HaCaT-E7 cells using the
ell lysis buffer as described above. Equal amounts ofotal protein were subjected to SDS–PAGE on a 10% gel
nd Western blotted. Blots were analyzed for the levels of
48, STAT1, and STAT2 using the following antibodies:
ouse anti-p48 monoclonal antibody (Transduction Lab-
ratories, Lexington, KY) diluted 1:500 in 1% skim milk in
BST, mouse anti-STAT1 monoclonal antibody (Santa
ruz Biotechnology) diluted 1:1000 in PBST, or rabbit
nti-STAT2 polyclonal antibody (Santa Cruz Biotechnol-
gy) diluted 1:5000 in 2.5% skim milk in PBST. Antibodies
ere detected using appropriate secondary antibodies,
abbit-anti-mouse-HRP conjugate (Silenus-Amrad) or
oat anti-rabbit-HRP conjugate (Sigma). Visualization
as achieved using ECL Plus according to the manufac-
urer’s instructions (Amersham).
In vitro transcription/translation. Linearized p48 plas-
id DNA (5 mg) was in vitro transcribed with T7 RNA
olymerase according to the manufacturer’s instructions
Promega, Australia). Following treatment with RQ1
Nase, RNA was phenol/chloroform extracted, ethanol
recipitated, and quantitated. For in vitro translation, 50
g of RNA was heated to 67°C for 10 min, cooled on ice,
nd added to 35 ml of rabbit reticulocyte lysate (nuclease
ree, Met2), 40 U RNasin, 1 ml of 1 mM amino acids
minus Met), and 4 ml of [35S]methionine/cysteine Trans-
abel (final concentration 0.8 mCi/ml) (ICN Biomedicals)
n a 50-ml volume and incubated at 30°C for 60 min.
E7 peptide binding assay. HPV16 E7 peptides GF101
amino acids 1–20) and GF103 (amino acids 17–37) were
ynthesized by and were a generous gift from Dr. Ger-
ain Fernando (CICR, Brisbane, Australia). HPLC-puri-
ied peptides (150 mg) were conjugated to cyanogen
romide-activated Sepharose beads (Sigma) using a
reviously published procedure (Dyson et al., 1992). Fol-
owing conjugation, the beads were washed in PBS be-
ore incubation in 3% BSA/PBS overnight at 4°C. Beads
ere again washed once in PBS and stored in PBS 1
.01% sodium azide. Conjugated peptide (15 mg) was
ixed with 5 ml of in vitro translated p48 for 1 h at 4°C
ith mixing. Following mixing, the beads were pulse-
entrifuged, washed three times in PBST, mixed with
DS–PAGE loading buffer, and boiled for 5 min. The
amples were subjected to SDS–PAGE on a 12% gel and
estern blot analysis for the presence of p48. Briefly, the
embrane was incubated with anti-p48 polyclonal anti-
ody (Santa Cruz Biotechnology) diluted 1:1000 in 2.5%
kim milk in PBST before incubation with goat anti-
abbit-HRP conjugate (Sigma) and positive signals were
etected by ECL Plus according to the manufacturer’s
nstructions.
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